Ab­b­Vie gets the FTC's di­vid­ed bless­ing for its $63B Al­ler­gan buy­out — free­ing Brent Saun­ders to blaze a new path

It may have tak­en a lit­tle longer than ex­pect­ed, or seemed like an ar­ti­fact from the pre-pan­dem­ic era. How­ev­er, Ab­b­Vie got the FTC’s OK to com­plete its mega $63 bil­lion buy­out of Al­ler­gan Tues­day evening.

The de­ci­sion fol­lowed a fa­mil­iar path at the FTC, break­ing along par­ty lines as Re­pub­li­cans lined up be­hind a plan to force some drug di­vesti­tures — a route that drew a scathing re­buke from Ro­hit Chopra, the De­moc­rats’ rep­re­sen­ta­tive who was backed by Re­bec­ca Kel­ly Slaugh­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER